Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia, also known as acute non-lymphocyte leukemia M3/ acute leukaemia M3 (ANLL- M3), is a 17, on the 15th chromosome Yi killer [t (15;17) (q22; q21)] special types of acute leukaemia, can be divided into two subtypes M3a and M3b.
For the clinical manifestations of anaemia, fever, bleeding, condyle of the four pain syndrome characterized by high blood vessels within the lungs it rich (DIC), serious bleeding, intracranial bleeding as a result of early mortality is very high.

Currently there are joint chemotherapy treatments commonly used, Weijiasuan induce differentiation and bone marrow transplant, although each has its advantages and disadvantages, but are not satisfied with the efficacy and unsatisfactory. Three long-term sustained mitigation rate (CCR) followed by 15~20%, 20%, about 50%. Joint chemotherapy drugs and side effects of large funds high (about five years 20~30 million); Weijiasuan complications as a result of extreme resistance and the four (high Weijiasuan, high white blood cell, high Luya and high histamine syndrome) affect its efficacy; Although the efficacy of bone marrow transplant (about 50%), but marrow sources difficulties, excessive requirements (about 40 million) and limited.

Leukaemia patients developed for efficient, low-cost, secure specific drug has been as a state Department of Labor social medicine experts, Professor Liu Shaanxi dream and mission. 10 years ago, Professor Liu arsenic found on tumors, particularly acute leukaemia cells as young tablets of a strong role, and found that the arsenic element itself non-toxic, and oxygen into oxide arsenic (arsenic) is highly toxic, a combination of sulphur and arsenic sulphide is non-toxic. He decisively established Chinese medicine Realgar (phonetic Ruierkang, four 4 arsenic sulphide, As4S4), the treatment of acute leukaemia cells as young tablets of research direction, a 28 Bo, a master student, launched Ruierkang element analysis, medicine generation dynamics, acute toxicity tests, cells, animal and human effectiveness, and mechanisms series based Applied Research, characterized in table 1. And completed 60 cases of side Ruierkang the treatment of acute leukaemia cells as young tablets of clinical research. Result : the complete guide to alleviate mitigate rate 93.23% (see table 2), five years of sustained rate of 96.43% ease (see table 3), and achieved encouraging results, and may replace the bone marrow transplant is a highly efficient, low-cost (about five years 3~5 million), security (see table 4), simple (outpatient mouth medication) specific drug.

The study has won state and the Shaanxi provincial government projects, research fund six projects, four of books, published more than 50 articles in papers, six articles by the U.S. scientific literature "Science> included, were assessed as" made alarming results "and received a number of awards University School of Medicine, the state invention patents, and national CME educational projects, Joint Ministry of Health and the Chinese Medical Association to the study "Diaowang and dividing tumour therapy" for the whole country to promote the use of approved projects (2005-03-10-009), by Professor Liu Shaanxi responsible for the annual observance of a national health researchers to study classes, and expand the applications.

The following references : Liu Shaanxi editor. Tumors Diaowu basis and applied research division. Xian : Shaanxi Science and Technology Press, 2005

Table 1 of the side Ruierkang features : Applied Research foundation

Table 2 of the side Ruierkang lure back young pills to alleviate the treatment of acute leukaemia cells 60 cases results

Table 3 56 cases of acute leukaemia cells as young Reap side Ruierkang consolidation treatment follow-up results *

* consolidation treatment time of five years

Table 4 of the side Ruierkang treatment of acute leukaemia cells as young tablets of the drug side-effects 60